Cargando…

[F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients

SIMPLE SUMMARY: Carcinoma of the uterine cervix is one of the most common and severe malignancies in women. Up to 40% of locally advanced cervical cancer patients treated with definitive chemoradiation therapy will not respond or will develop disease recurrence. The aim of this retrospective study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Ronit, Abdah-Bortnyak, Roxolyana, Amit, Amnon, Bar-Peled, Uval, Keidar, Zohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496806/
https://www.ncbi.nlm.nih.gov/pubmed/36139543
http://dx.doi.org/10.3390/cancers14184382
_version_ 1784794360474238976
author Gill, Ronit
Abdah-Bortnyak, Roxolyana
Amit, Amnon
Bar-Peled, Uval
Keidar, Zohar
author_facet Gill, Ronit
Abdah-Bortnyak, Roxolyana
Amit, Amnon
Bar-Peled, Uval
Keidar, Zohar
author_sort Gill, Ronit
collection PubMed
description SIMPLE SUMMARY: Carcinoma of the uterine cervix is one of the most common and severe malignancies in women. Up to 40% of locally advanced cervical cancer patients treated with definitive chemoradiation therapy will not respond or will develop disease recurrence. The aim of this retrospective study was to evaluate the relationship between quantitative metabolic and volumetric parameters extracted from FDG PET/CT imaging data and the response rate to definitive chemoradiation therapy in this group of patients. FDG PET/CT studies of 90 cervical cancer patients were analyzed, and it was found that quantitative metabolic and volumetric parameters such as SUVmax, SUVmean, MTV, and TLG are higher in locally advanced cervical cancer patients who will not respond to definitive chemoradiation therapy. Specifically, in patients who are not metastatic at staging, MTV and TLG values can serve as a predictor for treatment response and thus may alter treatment strategy. ABSTRACT: (1) Purpose: Current study aimed at evaluating the relationship between quantitative metabolic and volumetric FDG PET/CT parameters and the response to definitive chemoradiation therapy in locally advanced cervical cancer patients; (2) Methods: Ninety newly diagnosed locally advanced cervical cancer patients (FIGO IB2-IVA) were investigated. All patients underwent PET/CT at staging and after treatment. Metabolic and volumetric parameters, including SUVmax, SUVmean, Total Lesion Glycolysis (TLG), and Metabolic Tumor Volume (MTV) of the primary tumor and metastatic lymph nodes were measured and compared between patients with and without complete metabolic response (CMR). A similar analysis was performed in a subgroup of FIGO IB2-IIB patients; (3) Results: SUVmax and SUVmean of the primary tumor as well as those of metastatic lymph nodes, MTV, and TLG were found to be significantly different between CMR and non-CMR patients. In a subgroup of patients with FIGO IB2-IIB disease, MTV and TLG identified women who will achieve CMR with a threshold of 31.1 cm(3) for MTV and 217.8 for TLG; (4) Conclusions: PET/CT-derived quantitative metabolic and volumetric parameters are higher in locally advanced cervical cancer patients who will not respond to definitive chemoradiation therapy. Specifically, in patients who are not metastatic at staging, MTV and TLG values can serve as a predictor for treatment response and thus may alter treatment strategy.
format Online
Article
Text
id pubmed-9496806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94968062022-09-23 [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients Gill, Ronit Abdah-Bortnyak, Roxolyana Amit, Amnon Bar-Peled, Uval Keidar, Zohar Cancers (Basel) Article SIMPLE SUMMARY: Carcinoma of the uterine cervix is one of the most common and severe malignancies in women. Up to 40% of locally advanced cervical cancer patients treated with definitive chemoradiation therapy will not respond or will develop disease recurrence. The aim of this retrospective study was to evaluate the relationship between quantitative metabolic and volumetric parameters extracted from FDG PET/CT imaging data and the response rate to definitive chemoradiation therapy in this group of patients. FDG PET/CT studies of 90 cervical cancer patients were analyzed, and it was found that quantitative metabolic and volumetric parameters such as SUVmax, SUVmean, MTV, and TLG are higher in locally advanced cervical cancer patients who will not respond to definitive chemoradiation therapy. Specifically, in patients who are not metastatic at staging, MTV and TLG values can serve as a predictor for treatment response and thus may alter treatment strategy. ABSTRACT: (1) Purpose: Current study aimed at evaluating the relationship between quantitative metabolic and volumetric FDG PET/CT parameters and the response to definitive chemoradiation therapy in locally advanced cervical cancer patients; (2) Methods: Ninety newly diagnosed locally advanced cervical cancer patients (FIGO IB2-IVA) were investigated. All patients underwent PET/CT at staging and after treatment. Metabolic and volumetric parameters, including SUVmax, SUVmean, Total Lesion Glycolysis (TLG), and Metabolic Tumor Volume (MTV) of the primary tumor and metastatic lymph nodes were measured and compared between patients with and without complete metabolic response (CMR). A similar analysis was performed in a subgroup of FIGO IB2-IIB patients; (3) Results: SUVmax and SUVmean of the primary tumor as well as those of metastatic lymph nodes, MTV, and TLG were found to be significantly different between CMR and non-CMR patients. In a subgroup of patients with FIGO IB2-IIB disease, MTV and TLG identified women who will achieve CMR with a threshold of 31.1 cm(3) for MTV and 217.8 for TLG; (4) Conclusions: PET/CT-derived quantitative metabolic and volumetric parameters are higher in locally advanced cervical cancer patients who will not respond to definitive chemoradiation therapy. Specifically, in patients who are not metastatic at staging, MTV and TLG values can serve as a predictor for treatment response and thus may alter treatment strategy. MDPI 2022-09-08 /pmc/articles/PMC9496806/ /pubmed/36139543 http://dx.doi.org/10.3390/cancers14184382 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gill, Ronit
Abdah-Bortnyak, Roxolyana
Amit, Amnon
Bar-Peled, Uval
Keidar, Zohar
[F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title_full [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title_fullStr [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title_full_unstemmed [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title_short [F18]FDG PET/CT-Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
title_sort [f18]fdg pet/ct-derived metabolic and volumetric biomarkers can predict response to treatment in locally advanced cervical cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496806/
https://www.ncbi.nlm.nih.gov/pubmed/36139543
http://dx.doi.org/10.3390/cancers14184382
work_keys_str_mv AT gillronit f18fdgpetctderivedmetabolicandvolumetricbiomarkerscanpredictresponsetotreatmentinlocallyadvancedcervicalcancerpatients
AT abdahbortnyakroxolyana f18fdgpetctderivedmetabolicandvolumetricbiomarkerscanpredictresponsetotreatmentinlocallyadvancedcervicalcancerpatients
AT amitamnon f18fdgpetctderivedmetabolicandvolumetricbiomarkerscanpredictresponsetotreatmentinlocallyadvancedcervicalcancerpatients
AT barpeleduval f18fdgpetctderivedmetabolicandvolumetricbiomarkerscanpredictresponsetotreatmentinlocallyadvancedcervicalcancerpatients
AT keidarzohar f18fdgpetctderivedmetabolicandvolumetricbiomarkerscanpredictresponsetotreatmentinlocallyadvancedcervicalcancerpatients